

**From:** [Gelb, Bruce](#)  
**To:** [TOPMed ACC Publications](#); [b2bprogram@cchmc.org](mailto:b2bprogram@cchmc.org)  
**Cc:** [Sedlazeck, Fritz](#); [metcalf@bcm.edu](mailto:metcalf@bcm.edu)  
**Subject:** Re: TOPMed Manuscript Study-Specific Approval for PCGC  
**Date:** Wednesday, June 8, 2022 7:25:37 AM

---

**CAUTION: External Email \***

Ashley:

I confirm. Our study has previously approved this and continue to be supportive.

Please let me know if there are any additional questions or concerns.

Bruce

---

**From:** TOPMed ACC Publications <topmed-pubs@westat.com>  
**Date:** Tuesday, June 7, 2022 at 4:33 PM  
**To:** Bruce Gelb <bruce.gelb@mssm.edu>, "B2BProgram@cchmc.org" <b2bprogram@cchmc.org>  
**Cc:** TOPMed ACC Publications <topmed-pubs@westat.com>, "Sedlazeck, Fritz" <Fritz.Sedlazeck@bcm.edu>, "metcalf@bcm.edu" <metcalf@bcm.edu>  
**Subject:** TOPMed Manuscript Study-Specific Approval for PCGC

USE CAUTION: External Message.

Good Afternoon, Dr. Gelb.

I am reaching out to you on behalf of the TOPMed ACC Publications Team to confirm [study-specific approval](#) for Dr. Fritz Sedlazeck's manuscript "[Structural variation across 138,134 samples in the TOPMed consortium](#)" using the PCGC data. This manuscript has TOPMed Structural Variation Working Group Approval (see attached) and formal approval to use PCGC data (proposal #[12856](#)).

I will attach this email to Dr. Sedlazeck's TOPMed manuscript submission. He is cc'd on this email should you have any follow-up questions.

Best,

*Ashley Smith on behalf of the TOPMed ACC Publications Team*

**Ashley S. Smith, MPH, MLT(ASCP)**

WESTAT | *Public Health & Epidemiology Practice*

*o: 240-314-2344*

*c: 678-596-6467*

[AshleySmith@westat.com](mailto:AshleySmith@westat.com)

\* Please use caution when responding and/or clicking on links as this email originated from outside of Westat.

